HAEMOPHILIA

Scope & Guideline

Unraveling complexities in blood disorders.

Introduction

Welcome to the HAEMOPHILIA information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of HAEMOPHILIA, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN1351-8216
PublisherWILEY
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 1995 to 2024
AbbreviationHAEMOPHILIA / Haemophilia
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address111 RIVER ST, HOBOKEN 07030-5774, NJ

Aims and Scopes

The journal 'Haemophilia' serves as a key platform for advancing research and clinical practices related to bleeding disorders, specifically haemophilia and von Willebrand disease. It encompasses a wide array of topics, from novel therapeutic approaches to patient care strategies, aiming to improve outcomes for individuals with these conditions.
  1. Gene Therapy Research:
    The journal is at the forefront of publishing studies on gene therapies for haemophilia A and B, exploring the efficacy, safety, and long-term outcomes of such treatments.
  2. Clinical Management and Guidelines:
    It focuses on clinical practices, including the management of bleeding episodes, surgical interventions, and the development of treatment guidelines to standardize care across different healthcare settings.
  3. Patient-Centered Outcomes:
    Research highlighting the impact of haemophilia on quality of life, mental health, and psychosocial aspects is a core area, emphasizing the importance of patient-reported outcomes.
  4. Innovative Therapies and Technologies:
    The journal covers advancements in treatment modalities, including non-factor therapies, extended half-life products, and the use of technology in monitoring and managing haemophilia.
  5. Epidemiology and Health Economics:
    It includes studies on the epidemiology of bleeding disorders, healthcare utilization, and cost-effectiveness analyses related to different treatment approaches.
  6. Women and Bleeding Disorders:
    The journal addresses the unique challenges faced by women with bleeding disorders, including pregnancy management and heavy menstrual bleeding, which are critical for comprehensive care.
The journal has increasingly focused on several emerging themes, reflecting the latest advancements and priorities in the field of haemophilia and bleeding disorders.
  1. Personalized Medicine and Individualized Care:
    There is a growing emphasis on personalized treatment approaches, including pharmacogenomics and tailored prophylaxis strategies, aimed at optimizing outcomes for individual patients.
  2. Real-World Evidence and Patient Registries:
    The trend towards utilizing real-world data and patient registries to inform practice and guide treatment decisions is increasingly prominent in the journal's publications.
  3. Mental Health and Quality of Life:
    Research exploring the psychological aspects of living with haemophilia, including mental health challenges and quality of life assessments, is gaining more attention.
  4. Digital Health and Telemedicine:
    The impact of digital technologies and telehealth on patient management has emerged as a significant theme, particularly in light of the COVID-19 pandemic.
  5. Global Health Perspectives:
    There is a noticeable increase in studies addressing the global disparities in haemophilia care, focusing on low- and middle-income countries and their unique challenges.

Declining or Waning

While the journal continues to thrive in many areas, certain themes appear to be declining in prominence over time, possibly due to shifts in research focus or advancements in treatment options.
  1. Traditional Factor Replacement Therapy:
    As novel therapies like emicizumab and gene therapy gain traction, the frequency of publications focused solely on traditional factor replacement therapy has decreased.
  2. Acquired Haemophilia Studies:
    Research specifically addressing acquired haemophilia has become less frequent, as the focus shifts more toward inherited forms and their management.
  3. Historical Perspectives on Haemophilia Treatment:
    There seems to be a waning interest in historical analyses of treatment practices, as contemporary studies emphasize current and future treatment strategies.
  4. Basic Science Research:
    There is a noticeable reduction in publications dedicated to the fundamental biological mechanisms of haemostasis, as the journal increasingly prioritizes clinical and translational research.

Similar Journals

Blood Advances

Shaping the Landscape of Hematology Research
Publisher: ELSEVIERISSN: 2473-9529Frequency: 24 issues/year

Blood Advances is a premier, peer-reviewed journal published by Elsevier, dedicated to the field of hematology. With an impressive impact factor and classified within the Q1 category of hematology for 2023, it ranks as the 16th out of 137 journals in the Scopus Medicine Hematology category, placing it in the top 88th percentile globally. This influential journal, which has been disseminating invaluable research since its inception in 2017, focuses on advancing knowledge and innovation in blood science, including clinical and laboratory aspects of hematology. Although it offers limited open access features, its comprehensive scope encompasses various topics relevant to both researchers and practitioners. Located in the United States and managed from Amsterdam, Blood Advances provides a vital platform for the dissemination of groundbreaking research, making significant contributions to the understanding and treatment of blood disorders. Researchers, professionals, and students alike will find this journal an essential resource for keeping abreast of the latest developments and advancements in hematology.

Dermatologie

Empowering Knowledge in Skin Disease Management
Publisher: SPRINGER HEIDELBERGISSN: 2731-7005Frequency: 12 issues/year

Dermatologie, published by SPRINGER HEIDELBERG, is a prominent journal dedicated to the advancing field of dermatology. With its ISSN 2731-7005 and E-ISSN 2731-7013, this journal has established itself as a valuable resource for researchers, professionals, and students alike. Originating in Germany, the journal focuses on disseminating innovative research from 2022 to 2024, contributing significantly to the understanding of skin health and disease management. Despite its current ranking within the Q3 category in dermatology and a Scopus rank of #88/142, it provides critical insights and advances in clinical practice, epidemiology, and therapeutic modalities. With an emphasis on open discourse, it seeks to foster collaboration among healthcare professionals and researchers, thereby enhancing the quality and accessibility of dermatological research. Engage with Dermatologie to stay at the forefront of the latest advancements in skin-related health issues.

Research and Practice in Thrombosis and Haemostasis

Leading the way in thrombosis and hemostasis research.
Publisher: ELSEVIERISSN: Frequency: 8 issues/year

Research and Practice in Thrombosis and Haemostasis, published by Elsevier, is a prominent open-access journal dedicated to advancing the field of hematology through high-quality research and clinical practice. Since its inception in 2017, this journal has established itself as a vital resource for researchers, healthcare professionals, and students interested in thrombosis and hemorrhage management, showcasing original research, reviews, and clinical studies. The journal’s commitment to accessible knowledge is reflected in its open-access model, allowing researchers worldwide to share their findings without financial barriers. With an impressive 2023 Scopus rank of #42 out of 137 in the hematology category and a respectable Q2 classification, it provides an authoritative platform for innovative ideas and cutting-edge developments in the field. As the journal continues to grow in stature, it aims to foster collaboration and knowledge exchange amongst professionals dedicated to improving patient outcomes in thrombosis and hemostasis.

Hamostaseologie

Transforming Hematological Knowledge: Essential Insights for Professionals
Publisher: GEORG THIEME VERLAG KGISSN: 0720-9355Frequency: 4 issues/year

Hamostaseologie is a prominent academic journal dedicated to the field of hematology, published by GEORG THIEME VERLAG KG. With an ISSN of 0720-9355 and an E-ISSN of 2567-5761, this journal has been at the forefront of critical research and advancements since its inception in 1981, and it continues to maintain its relevance in the scientific community with a converged publication until 2024. Ranked in the Q3 quartile in Hematology for 2023, and positioned at #44 out of 137 in the Scopus Medicine Hematology category, it represents a substantial contribution to scholarly discourse. Researchers and professionals alike will find valuable insights within its pages, as it disseminates rigorous studies and reviews that address pertinent issues related to hemostasis and coagulation. While the journal does not currently offer Open Access, readers can access its valuable content through institutional subscriptions, making it an essential resource for students, clinicians, and researchers aiming to deepen their understanding of hematological science.

Current Urology

Bridging Theory and Practice in Urology and Beyond
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1661-7649Frequency: 4 issues/year

Current Urology, published by Lippincott Williams & Wilkins, is a leading journal dedicated to advancing the fields of urology, oncology, and reproductive medicine. With an ISSN of 1661-7649 and E-ISSN of 1661-7657, this journal has established itself as a valuable resource for researchers, practitioners, and students alike, providing peer-reviewed articles that contribute to the ongoing discourse and development of these critical specialties. Operating out of the United States, Current Urology ranks in the third quartile for oncology, reproductive medicine, and urology, reflecting its importance in the medical community. The journal’s focus on innovative research and clinical practice allows it to bridge gaps between theoretical understanding and practical application, enhancing patient care and outcomes. Although currently not an open-access journal, it offers a wealth of insights and findings that underpin contemporary urological practices and research. In an evolving medical landscape, Current Urology remains an essential platform for disseminating knowledge and fostering collaboration among experts in the field.

BLOOD REVIEWS

Advancing the frontiers of Hematology and Oncology.
Publisher: CHURCHILL LIVINGSTONEISSN: 0268-960XFrequency: 6 issues/year

BLOOD REVIEWS is a highly regarded journal published by Churchill Livingstone, specializing in the fields of Hematology and Oncology. With an impressive Q1 ranking in both disciplines and placing in the top 10% of its peer categories according to Scopus metrics, it provides an essential platform for the dissemination of cutting-edge research and reviews pertaining to blood disorders and cancer treatment. Since its inception in 1987 and continuing through 2024, the journal has established itself as a cornerstone for healthcare professionals, researchers, and students who seek to advance their understanding of hematologic and oncologic topics. While not an open-access journal, BLOOD REVIEWS retains a reputation for delivering high-quality, peer-reviewed articles that foster dialogue and innovation within the scientific community. For those in the United States and beyond, the journal serves as a vital resource, housed at the Journal Production Department in Edinburgh, Scotland, ensuring accessibility and a global reach in its critical academic contributions.

Movement Disorders Clinical Practice

Navigating the complexities of movement disorders together.
Publisher: WILEYISSN: 2330-1619Frequency: 8 issues/year

Movement Disorders Clinical Practice, published by WILEY, is an essential peer-reviewed journal dedicated to advancing the understanding and treatment of movement disorders from a clinical perspective. With an ISSN of 2330-1619, this journal serves as a vital resource for researchers, clinicians, and students engaged in neurology and clinical neuroscience. Since its inception in 2014, the journal has established itself within the medical community, currently positioned in the Q2 category for both Neurology and Neurology (Clinical), reflecting its influence and reputation. Although it does not offer open access, the journal is integral for disseminating high-quality research and clinical insights, thereby contributing significantly to improved patient care and outcomes in the field of movement disorders. Based in Hoboken, NJ, it continues to attract contributions from leading experts and aims to foster a deeper understanding and dialogue surrounding contemporary challenges and advancements in movement disorder treatment.

Turkish Journal of Hematology

Advancing hematological research for a healthier tomorrow.
Publisher: GALENOS PUBL HOUSEISSN: 1300-7777Frequency: 4 issues/year

Turkish Journal of Hematology is an esteemed publication dedicated to advancing the field of hematology, producing influential research since its inception in 1999 under the auspices of GALENOS PUBL HOUSE. With an Open Access model, it facilitates widespread dissemination of knowledge, allowing researchers, clinicians, and students to stay abreast of the latest developments in blood disorders and treatments. With an ISSN of 1300-7777 and an E-ISSN of 1308-5263, the journal holds a commendable position in the academic community, evidenced by its 2023 Q3 ranking within the hematology category and its standing at #80 out of 137 in the Scopus database, placing it in the 41st percentile. Covering a wide scope of topics within hematology, this journal serves as a critical resource for disseminating innovative research and clinical practices pertinent to the ongoing challenges faced in this vital area of medicine. With its continuous publication until 2024, Turkish Journal of Hematology remains a beacon for enhancing the understanding and treatment of hematological conditions within the Turkish and global medical communities.

Thalassemia Reports

Advancing knowledge in thalassemia research.
Publisher: MDPIISSN: 2039-4357Frequency: 4 issues/year

Thalassemia Reports is a distinguished journal dedicated to the field of hematology, focusing on the implications, management, and advancements related to thalassemia and related disorders. Published by MDPI, a renowned open-access publisher, this journal has been committed to disseminating high-quality research since its inception in 2011. With an ISSN of 2039-4357 and an E-ISSN of 2039-4365, it serves as an invaluable resource for researchers, clinicians, and students alike who are engaged in the study of hemoglobinopathies. The journal fosters easy access to peer-reviewed articles that contribute to the understanding and management of thalassemia, thus promoting collaborative efforts within the academic and medical communities. The open-access model ensures that critical findings are widely available to the global audience, enhancing knowledge exchange and innovation in the field.

NEUROMUSCULAR DISORDERS

Elevating the standard of care through scientific excellence.
Publisher: PERGAMON-ELSEVIER SCIENCE LTDISSN: 0960-8966Frequency: 12 issues/year

NEUROMUSCULAR DISORDERS is a premier academic journal published by PERGAMON-ELSEVIER SCIENCE LTD, focusing on the latest research and developments in the fields of neurology, genetics, and pediatric health. With an ISSN of 0960-8966 and an E-ISSN of 1873-2364, this journal has established a significant presence since its inception in 1991, and it continues to contribute to the scientific community with its impactful findings and reviews. The journal boasts a commendable impact factor, reflected in its placement in the Q2 category for Clinical Genetics and Neurology, as well as its positioning in the top tier Q1 for Pediatrics, Perinatology and Child Health according to the latest quartile assessments. With Scopus rankings such as Rank #71/330 in Pediatrics and Rank #51/99 in Clinical Genetics, NEUROMUSCULAR DISORDERS is recognized for its contribution to advancing knowledge in neuromuscular diseases. The journal is essential for researchers, clinicians, and students interested in the intricate relationship between genetics and neurological disorders, providing valuable insights that drive innovation and improve patient care.